Comparative Pharmacology
Head-to-head clinical analysis: HYDERGINE LC versus WIGRAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDERGINE LC versus WIGRAINE.
HYDERGINE LC vs WIGRAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates (dihydroergotoxine) act as a partial agonist/antagonist at dopamine (D1, D2), serotonin (5-HT1, 5-HT2), and alpha-adrenergic receptors. They enhance cerebral metabolism and increase blood flow via vasodilation and neuroprotection.
WIGRAINE is a combination product containing ergotamine, a vasoconstrictor that acts as an agonist at serotonin (5-HT1B/1D) and alpha-adrenergic receptors, and caffeine, which enhances ergotamine absorption and provides additional vasoconstriction.
Oral, 1 mg three times daily. Titrate up to 2 mg three times daily if needed.
For acute migraine: 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack, maximum 10 tablets per week.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours. Clinical context: steady-state achieved in 2–3 days; allows once-daily dosing.
Ergotamine: ~2-3 hours (terminal). Clinical context: short half-life necessitates frequent dosing for acute migraine relief.
Renal (80% as metabolites, <1% unchanged); biliary/fecal (20%).
Primarily hepatic metabolism; renal excretion of metabolites. ~90% urinary, ~10% fecal.
Category C
Category C
Ergot Alkaloid
Ergot Alkaloid